The filing itself does not halt trading, but the request signals that management believes trading is not occurring in a fair and orderly market. Watch for Nasdaq's decision on the suspension request and any further developments in the Delaware litigation. If Nasdaq grants the suspension, LNAI shares would become illiquid until the suspension is lifted.
Price Chart
Executive Summary
Lunai Bioworks submitted a formal request to Nasdaq on October 9, 2026, asking for an immediate trading suspension in its common stock, citing court-ordered discovery records that it claims reveal substantial short selling, locate deficiencies, and concentrated failures to deliver. The request is tied to its pending litigation against Seven Points Capital LLC. Nasdaq has not yet responded, and trading continues normally for now.
Key Facts
- Lunai Bioworks submitted an urgent request to Nasdaq on October 9, 2026, asking for an immediate suspension of trading in LNAI common stock.
- The request is based on court-ordered discovery records described in the Company's Second Amended Complaint filed August 26, 2026, alleging substantial short selling, locate deficiencies, and concentrated failures to deliver.
- The request is part of the pending litigation Lunai Bioworks, Inc. v. Seven Points Capital LLC et al., Case No. 1:26-cv-00549-CFC, in the U.S. District Court for the District of Delaware.
- Nasdaq has not yet responded to the request; the Company cannot predict when or if Nasdaq will act.
- The request itself does not halt trading — any suspension decision remains solely with Nasdaq.
Financial Impact
No financial figures provided in the filing. The request seeks a trading suspension, which if granted would halt all trading in LNAI common stock indefinitely.
Risk Factors
- Nasdaq could grant the trading suspension request, halting all trading in LNAI common stock indefinitely.
- The pending litigation against Seven Points Capital LLC may result in adverse findings or sanctions.
- The allegations of market manipulation, if substantiated, could lead to regulatory investigations or enforcement actions.
- Continued negative sentiment from the allegations could further pressure the stock price even without a formal suspension.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001731122-26-001333 |
| Document: 0001731122-26-001333-index-headers.html | 0001731122-26-001333 |
| Document: 0001731122-26-001333-index.html | 0001731122-26-001333 |
| Document: 0001731122-26-001333.txt | 0001731122-26-001333 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $0.3800 | awaiting T+5 | — | $0.2664 (+29.89%) |
Oct 15, 2026 10d ago | SC 13D/A | $0.6800 $0.2950 | ▲ +56.62% | ▲ +56.19% | $0.2664 (+60.82%) |
Oct 9, 2026 16d ago | 8-K | $1.23 $0.6800 | ▲ +44.72% | ▲ +42.75% | $0.2664 (+78.34%) |
Sep 29, 2026 26d ago | NT 10-K | $1.47 $1.09 | ▲ +25.85% | ▲ +27.76% | $0.2664 (+81.88%) |
Jun 17, 2026 18w ago | 8-K | $3.78 $3.56 | ▼ −5.82% | ▼ −4.15% | $0.2664 (−92.95%) |
Jun 16, 2026 18w ago | 8-K | $4.00 $3.43 | ▼ −14.25% | ▼ −13.21% | $0.2664 (−93.34%) |
May 20, 2026 22w ago | 8-K | $1.80 $2.62 | ▼ −45.56% | ▼ −44.32% | $0.2664 (+85.20%) |
May 1, 2026 25w ago | 8-K | $2.60 $2.59 | ▼ −0.22% | ▼ −3.15% | $0.2664 (−89.74%) |
Apr 28, 2026 25w ago | DEFA14A | $2.66 $2.50 | ▼ −6.01% | ▼ −9.12% | $0.2664 (−90.00%) |
Mar 5, 2026 33w ago | 8-K | $1.86 $1.48 | ▲ +20.59% | ▲ +19.06% | $0.2664 (+85.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers